Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology | Family Medicine
Disease Category: Depression (Major/Severe)
Location: United States, IL
Clinical Trial Details
Research Study Summary
An 8-week, randomzied, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of agomelatine 0.5mg and 1mg sublingual tablets administered once daily in patients with Major Depressive Disorder (MDD).
The purpose of this study is to find out if two different doses of agomelatine are safe and tolerable, and can help people who have major depressive disorder. The study doctor will also give agomelatine to some people in this study to find out if taking agomelatine is better than taking placebo. Placebo is a tablet that looks like an active drug but has no drug or other active ingredient
Please contact Alexian Brothers for more information on participation.
To Learn more
Both Male and Female
Date Last Changed:
July 22, 2013
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.